secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001437749-25-033604
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma raises 2025 guidance; Q3 GAAP net income $8.8M vs $20.3M YoY on lower royalty revenue
--------------------------------------------------------------------------------

- Q3 GAAP net income $8.8M ($0.17 diluted) vs $20.3M ($0.41) YoY; non-GAAP adj. net income $10.5M ($0.21) vs $22.4M ($0.46).
- Q3 product revenue $51.9M (vs $56.1M); total revenue $54.5M (vs $80.5M) driven by lower royalty from China licensee.
- Updated FY2025 guidance: product revenue $198-200M, total revenue $220-223M, net income $27-29M (all raised from prior).
- Cash & securities $94.4M at Sep 30, 2025; operating cash flow $9.7M in Q3.
- Interim data from ALISCA-Breast1 and ALISCA-Lung1 alisertib trials expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774925033604/0001437749-25-033604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774925033604/pbyi20250901_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-033604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer